Full-Time
Confirmed live in the last 24 hours
Develops medicines for epigenetic reprogramming
Senior, Expert
San Bruno, CA, USA
You match the following NewLimit's candidate preferences
Employers are more likely to interview you if you match these preferences:
NewLimit develops medicines aimed at extending human healthspan by reprogramming aging cells' epigenomes. This process involves changing the chemical modifications on DNA and histone proteins to restore youthful functions in old cells, focusing initially on rejuvenating the immune system and liver. The company utilizes advanced technologies like single-cell genomics, machine learning, and high-throughput functional assays to identify aging markers and create interventions that reverse these changes. NewLimit serves the healthcare market, targeting patients with age-related diseases and collaborating with pharmaceutical companies and healthcare providers. Its goal is to create a new class of medicines that significantly increase the duration of healthy living.
Company Size
11-50
Company Stage
Series A
Total Funding
$38.9M
Headquarters
South San Francisco, California
Founded
2022
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Parental Leave
Unlimited Paid Time Off
NewLimit works across cell biology, genomics, machine learning, and cellular reprogramming to treat diseases and reverse aging
NewLimit aims to increase the number of healthy years each person lives by epigenetically reprogramming cells.
NewLimit, a startup that aspires to reverse aging by manipulating cells, announced on Tuesday that it’s raised $40 million in a Series A round from Kleiner Perkins and other venture firms, and from prominent individuals like former Google CEO Eric Schmidt and Y Combinator CEO Garry Tan.